For over 30 years, I have been researching a protein called Galectin-3. It’s a key player in a long list of chronic health conditions, including cardiovascular and circulatory issues.
While you may not have heard of galectin-3, thousands of published studies show that when Galectin-3 goes into overdrive, it fuels numerous disease processes and can actually shorten your life.
The Problem With Galectin-3
Galectin-3 is a carbohydrate-binding protein normally present in the body at low concentrations. It is expressed in various cell types and tissues, including endothelial cells (lining blood vessels) and epithelial cells (covering organ surfaces, including the heart).
Galectin-3’s chief role is that of a “survival protein.” When your body faces a physical or emotional threat, it goes into survival mode, and Galectin-3, as the “survival protein,” is activated. It then triggers a short-term inflammatory response designed to stimulate a repair process..
I want to emphasize the word short-term because Galectin-3 is not meant to be circulating in your system in elevated levels on a regular basis. It’s only when you are dealing with a serious health threat or injury that the production of this protein spikes—the body should stop making excessive amounts of it once that threat is resolved.
Herein lies the problem with Galectin-3. It has the ability to spike very quickly and start a cascade of immune and inflammatory responses, which is termed immune and inflammatory dysregulation. But it doesn’t turn off! So many of us are living in a constant state of survival mode these days, causing our bodies to artificially stay on high alert—and continue producing Galectin-3 even when it’s not needed.
This fuels chronic systemic inflammation (inflammatory cytokine signals) and fibrosis (uncontrolled scar tissue build-up), both of which contribute to organ failure, premature aging, and chronic disease.
But what causes our bodies to perceive immediate danger when there really is none? Our modern lifestyles leave us primed for this—factors such as unrelenting stress, increased toxin exposure, poor sleep hygiene, gut problems, and immune system imbalances keep the body in survival mode for extended periods of time. And all areas of our health and wellness are negatively impacted as a result.
Thousands of studies illustrate Galectin-3’s role in driving many serious health problems, starting with cancer, the focus of Galectin-3 research in the 90s, and continuing with kidney failure, obesity, Alzheimer’s, autoimmune conditions, arthritis, mold and mycotoxin illness, mast cell activation syndrome, and cardiovascular disease.
Galectin-3 and Heart Disease
Galectin-3 is a key indicator of cardiac health and a primary agent in heart failure and fibrosis. An increase in Galectin-3 expression and its presence in the circulation have been linked to heightened fibrosis, heart failure, and inflammation (the hallmark of arteriosclerosis). Elevated Galectin-3 levels also contribute to coronary artery disease, peripheral artery disease, and strokes.
In terms of artery disease, Galectin-3 sets the stage where arteriosclerotic plaques can form. It actually accelerates the development of atherosclerotic plaques (through inflammatory mechanisms) while simultaneously promoting cardiac remodeling and stiffening through fibrosis.
In heart failure, excess Galectin-3 is implicated in a range of processes, including myofibroblast proliferation, inflammation and fibrogenesis, tissue repair, and ventricular and tissue remodeling. Elevated levels of Galectin-3 in the blood are associated with significant increases in heart attack risk, risk of death in acute decompensated heart failure, and chronic heart failure.
To elaborate, Galectin-3 levels can dramatically affect outcomes in cases of heart failure. Studies have shown that patients with lower Galectin-3 levels have a better prognosis than those with higher levels, who are more likely to develop fibrotic heart failure, which is harder to treat.
How significant? If you have heart failure and your Galectin-3 is under 17.8, your all-cause mortality—your chance of dying from any cause in the next 12 months—is about 12.5%, or ⅛. But, if your Galectin-3 is greater than 25.6, your all-cause mortality triples to over 37%!
This problematic protein also serves as the backbone of biofilm formations in the body, which sequester toxins and pathogens in inflamed, isolated areas shielded from immune surveillance and treatments. It creates an environment where bacteria, viruses, and toxins can thrive.
So as you can see, Galectin-3 isn’t just a biochemical marker—it’s also an active participant in cardiovascular disease pathology.
What Can You Do?
Here are some steps you can take, along with a few links for more information about managing Galectin-3 levels for improved heart health:
- Check Your Levels: Talk to your doctor about getting a Galectin-3 blood test. It’s available through Quest Diagnostics and LabCorp. Knowing your levels can provide valuable insights into your heart health.
- Manage Inflammation: Focus on practices that shift your body into a parasympathetic mode. Deep breathing, relaxation, and meditation can help balance your autonomic nervous system and ease inflammation.
- Support Kidney Function: Since Galectin-3 is excreted through the kidneys, maintaining kidney health is crucial.
- Hydration: Drinking enough water is key for heart health.
- Supplement: Take modified citrus pectin, a natural galectin-3 blocker that has been studied in cardiovascular diseases.
A Note About the Heart’s Healing Power
The heart is truly a remarkable organ. It’s the sole organ that nourishes itself only after it has finished its work, offering to others first. This selflessness is at the core of its healing power. Interestingly, Galectin-3 is connected to our emotional state. Isolation can cause Galectin-3 levels to rise, further isolating our hearts emotionally.
Remember, the heart can move from a place of resentment to one of acceptance, love, and compassion, affecting every cell in our body and the people around us.
Final Thoughts
The direct link between Galectin-3 and numerous acute and chronic diseases is what gives this protein such important diagnostic and therapeutic implications. Unlike the popular biomarker C-Reactive Protein (CRP), which only indicates the presence of inflammation, elevated circulating Galectin-3 is recognized as an “active” or “culprit” biomarker. Therefore, Galectin-3 plays a dual role as both a diagnostic marker and an important therapeutic target.
References
Legrand M, Rossignol P. Cardiovascular Consequences of Acute Kidney Injury. N Engl J Med. 2020 Jun 4;382(23):2238-2247. doi: 10.1056/NEJMra1916393. PMID: 32492305.
Prud’homme M, Coutrot M, Michel T, Boutin L, et al. Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway. JACC Basic Transl Sci. 2019 Oct 28;4(6):717-732. doi: 10.1016/j.jacbts.2019.06.005. PMID: 31709320; PMCID: PMC6834958.
Wyler von Ballmoos M, Likosky DS, Rezaee M, et al. Elevated preoperative Galectin-3 is associated with acute kidney injury after cardiac surgery. BMC Nephrol. 2018 Oct 20;19(1):280. doi: 10.1186/s12882-018-1093-0. PMID: 30342486; PMCID: PMC6195960.
Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015 Jan;3(1):59-67. doi: 10.1016/j.jchf.2014.08.002. Epub 2014 Nov 11. PMID: 25458174.
De Boer RA. Galectin-3 Levels & Mortality from All Causes in the General Population: PREVEND The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results presented at the European Society of Cardiology (ESC) Congress (Aug) 2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population.”
deFilippi , CR, Felker, GM. Galectin-3 in Heart Failure—Linking Fibrosis, Remodeling, and Progression. U.S. Cardiology. 2010;7;1: 3–6.
De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–7.
De Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43;1:60-8.
Psarras S, Mavroidis M, Sanoudou D, Davos CH, Xanthou G, Varela AE, et al. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Eur Heart J. 2011; 20
Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12;8:826-32.
Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010 May;99(5):323-8.
Li S, Li S, Hao X, Zhang Y, Deng W. Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. Front Physiol. 2019 Mar 22;10:267. doi: 10.3389/fphys.2019.00267. PMID: 30967790; PMCID: PMC6438875.
